How I explore... A risk difference in the occurrence of an event in clinical trials;Comment j'Explore... Une différence de risque de survenue d'un événement dans les études cliniques

Revue Medicale de Liege

Volumn 67, Issue 11, 2012, Pages 597-602

  Scheen, A J ^a,b   Ernest, P ^b   Jandrain, B ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Drug; Efficacy; Evidence based medicine; Outcomes; Randomised clinical trials; Statistical analysis

Indexed keywords

ARTICLE; ATTRIBUTABLE RISK; CONTROLLED CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; HAZARD RATIO; HUMAN; RISK FACTOR; RISK REDUCTION;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG TOXICITY; HUMANS; NUMBERS NEEDED TO TREAT; PLACEBOS; RISK; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 84872079619     PISSN: 0370629X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Scheen AJ.- Evidence-based medicine. Apport des essais cliniques contrôlés. Rev Med Liège, 2000, 55, 216-219.
2. Scheen AJ.- La mesure de l'efficacité thérapeutique, étape essentielle dans la médecine factuelle. Rev Med Liège, 2000, 55, 206-210.
3. Laupacis A, Sackett DL, Roberts RS.- An assessment of clinically useful measures of the consequences of treatment. N Eng J Med, 1988, 318, 1728-1733.
4. Collins R, MacMahon.- Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet, 2001, 357, 373-380. (Pubitemid 32128549)
5. Scheen AJ.- Comment j'explore ... les critères de jugement dans les essais cliniques : réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège, 2006, 61, 260-266. (Pubitemid 43873002)
6. Piérard GE, Scheen AJ.- Innover par l'EBM. Glossaire initiatique aux recherches cliniques. Rev Med Liège, 2005, 60, 190-194.
7. Replogle WH, Johnson WD.- Interpretation of absolute measures of disease risk in comparative research. Fam Med, 2007, 39, 432-435. (Pubitemid 46871364)
8. Rodondi N, Cornuz J.- Lecture d'articles médicaux: quelques pièges à éviter. Rev Med Suisse, 2007, 3, 2718-2723. (Pubitemid 350254085)
9. Bergmann JF, Chassany O.- Lire un compte rendu d'essai clinique. Rev Prat, 2000, 50, 838-845. (Pubitemid 30243532)
10. Morabia A.- Risque relatif et odds ratio. Rev Mal Resp, 2003, 20, 757-759.
11. Bucher HC, Weinbacher M, Gyr K.- Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ, 1994, 309, 761-764. (Pubitemid 24291634)
12. Spruance SL, Reid JE, Grace M, Samore M.- Hazard ratio in clinical trials. Antimicrob Agents Chemother, 2004, 48, 2787-2792.
13. Lee ET, Go OT.- Survival analysis in public health research. Annu Rev Public Health, 1997, 18, 105-134. (Pubitemid 27194066)
14. Cook RJ, Sackett DL.- The number needed to treat: a clinically useful measure of treatment effect. BMJ, 1995, 310, 452-454. Erratum in : BMJ, 1995, 310, 1056.
15. Hutton JL.- Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol, 2009, 146, 27-30.
16. Stang A, Poole C, Bender R.- Common problems related to the use of number needed to treat. J Clin Epidemiol, 2010, 63, 820-825.
17. Norman GR, Streiner DL.- Do CIs give you confidence? Chest, 2012, 141, 17-19.
18. Rothwell PM.- Treating individuals 2. Subgroup analysis in randomised controlled trials : importance, indications, and interpretation. Lancet, 2005, 365, 176-186. (Pubitemid 40091809)
19. Detsky AS, Sackett DL.- When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med, 1985, 145, 709-712. (Pubitemid 15077939)
20. Mélot C.- Que signifie puissance d'une étude ? Comment la calculer ? Comment calculer le nombre de sujets nécessaires ? Rev Mal Respir, 2003, 20, 602-603. (Pubitemid 37214555)
21. Scheen AJ.- Comment j'explore ... les secrets d'une méta-analyse. Rev Med Liège, 2003, 58, 41-46. (Pubitemid 36188357)